Atovaquone oral suspension used for prevention and treatment of a type of pneumonia.
New Delhi: Drug firm Lupin said it has received a approval from the US health regulator to market its Atovaquone oral suspension used for prevention and treatment of a type of pneumonia. The company has received approval to market generic Atovaquone oral suspension USP in the strength of 750 mg/5 mL from the United States Food and Drug Administration (USFDA), Lupin said in a BSE filing.
The product is a generic version of GlaxoSmithKline LLC’s Mepron oral suspension in the same strength, it added.
As per IQVIA MAT June 2018 data, Atovaquone oral suspension, 750 mg/5 mL had annual sales of around USD 117.4 million in the US, Lupin said.
The product is “indicated for the prevention and acute oral treatment of mild-to-moderate pneumocystis carinii pneumonia (PCP) in patients intolerant to trimethoprim-sulfamethoxazole,” it added.
At Medical Dialogues, we are a team of young professionals strongly advocating of the transparency in the medical sector through the free flow of medical information, health and medical news.
MD Team covers a variety of news related to the healthcare, pharma and medical device industry in India. Our team can be contacted at firstname.lastname@example.org Contact no. 011-43720751